The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Evaluating the combination of nivolumab and lenalidomide in relapsed HL and LBCL
David Bond, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses the results of a Phase I/II study evaluating the combination of nivolumab and lenalidomide in patients with relapsed Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Dr Bond highlights the results obtained in both patient cohorts, and further comments on the efficacy of this combination. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
